Urogen Pharma (NASDAQ:URGN) Share Price Breaks Below Two Hundred Day Moving Average on Disappointing Earnings

Key Points

• UroGen shares fell below their 200-day moving average, trading as low as $27.55, after quarterly results and reduced FY2026 guidance disappointed investors. The company reported a $0.03-per-share loss and $89 million in revenue, slightly below the cited analyst estimates.
• ZUSDURI delivered $68 million in third-quarter revenue, up 35% sequentially, with repeat prescribers accounting for half of its writers. The FDA also accepted UGN-103 for review, setting a June 14, 2027 target decision date.

Urogen Pharma (NASDAQ:URGN - Get Free Report) passed below its 200-day moving average during trading on Wednesday following a dissappointing earnings announcement. The stock has a 200-day moving average of $31.46 and traded as low as $27.55. Urogen Pharma shares last traded at $28.74, with a volume of 2,897,423 shares changing hands.

The company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of $0.11 by ($0.14). The company had revenue of $89.00 million for the quarter, compared to analyst estimates of $89.92 million.

Urogen Pharma News Summary

Here are the key news stories impacting Urogen Pharma this week:

• Positive Sentiment: ZUSDURI generated $68 million in third-quarter revenue, up 35% sequentially. The company also said repeat prescribers made up 50% of ZUSDURI writers, suggesting growing adoption. The Gel That Became a Business
• Positive Sentiment: The FDA accepted UroGen’s UGN-103 application for review and set a June 14, 2027 PDUFA goal date, providing a regulatory milestone for the next-generation therapy. UroGen also reported that the first patient was dosed in its UGN-501 Phase 1 trial. UroGen Q3 2026 results and highlights
• Negative Sentiment: UroGen cut its FY2026 guidance, a key source of investor concern. Although ZUSDURI sales were strong, reported quarterly revenue of $89 million was slightly below the cited $89.92 million consensus, and earnings coverage characterized the results as missing estimates. The company reported a loss of $0.03 per share; estimate comparisons varied across reports. UroGen stock falls on Q3 results and guidance cut

Wall Street Analyst Weigh In

URGN has been the topic of several research analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Urogen Pharma in a report on Thursday, October 15th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $44.00 price target on shares of Urogen Pharma in a report on Wednesday, July 15th. Jefferies Financial Group reiterated a "buy" rating and issued a $56.00 price target on shares of Urogen Pharma in a report on Thursday, September 10th. HC Wainwright reissued a "buy" rating and set a $75.00 price objective on shares of Urogen Pharma in a research report on Monday, October 19th. Finally, UBS Group restated a "buy" rating on shares of Urogen Pharma in a report on Thursday, July 9th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $52.38.

Insiders Place Their Bets

In related news, insider Mark Schoenberg sold 871 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $42.92, for a total transaction of $37,383.32. Following the completion of the transaction, the insider directly owned 59,882 shares of the company's stock, valued at approximately $2,570,135.44. This represents a 1.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Jason Smith sold 1,519 shares of the firm's stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $42.54, for a total transaction of $64,618.26. Following the completion of the transaction, the general counsel directly owned 53,141 shares of the company's stock, valued at $2,260,618.14. This represents a 2.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 65,269 shares of company stock valued at $3,037,646 in the last three months. 4.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Urogen Pharma

Institutional investors and hedge funds have recently made changes to their positions in the company. Sterling Capital Management LLC increased its position in Urogen Pharma by 442.1% during the third quarter. Sterling Capital Management LLC now owns 1,339 shares of the company's stock worth $54,000 after acquiring an additional 1,092 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Urogen Pharma by 15.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,919 shares of the company's stock valued at $361,000 after purchasing an additional 1,165 shares during the period. Persistent Asset Partners Ltd bought a new stake in Urogen Pharma in the 2nd quarter valued at about $66,000. Quantbot Technologies LP bought a new stake in Urogen Pharma in the 2nd quarter valued at about $78,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Urogen Pharma during the 3rd quarter worth approximately $101,000. Institutional investors and hedge funds own 91.29% of the company's stock.

Urogen Pharma Trading Down 16.5%

The stock's 50-day simple moving average is $39.60 and its 200-day simple moving average is $31.46. The stock has a market cap of $1.40 billion, a price-to-earnings ratio of -14.52 and a beta of 1.68.

About Urogen Pharma

UroGen Pharma Ltd. NASDAQ: URGN is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company's therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen's primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen's proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.